Main therapeutic interventions in the management of patients with non-Hodgkin's lymphoma
DOI:
https://doi.org/10.33448/rsd-v11i14.36400Keywords:
Lymphoma, non-Hodgkin; Chemotherapy; Recurrence.Abstract
Objective: to identify the main therapeutic interventions in the management of patients with non-Hodgkin's lymphoma. Material and methods: In order to answer the research question “What are the main therapeutic interventions in the management of patients with non-Hodgkin's lymphoma?”, a systematic review of the literature was chosen. The research will be carried out through a search, based on a search strategy, in the Medical Publisher (PUBMED) and Science Direct databases, with the objective of selecting articles related to therapeutic interventions in the management of patients with non-invasive lymphoma. -Hodgkin. Results: the association of rituximab with chemotherapy and with lenalidomide may allow prolonged responses in some patients and represents an effective therapeutic option. The high-dose chemotherapy strategy with autologous stem cell transplantation has been shown to be viable and highly effective in patients with primary central nervous system lymphoma, providing a better prognosis for patients. Final considerations: it is possible to state that the therapy of choice initially for the management of patients with non-Hodgkin's lymphoma still continues to be the association of rituximab with chemotherapy in the R-CHOP regimen, with the possibility of still being associated with lenalidomide, allowing answers prolonged in some patients and representing an effective therapeutic option. Maintenance therapy with rituximab has been shown to improve progression-free survival in patients with follicular lymphoma, improving survival rates and the duration of disease remission. Combined modality therapy (chemotherapy + immunotherapy) may have better outcomes and prognosis for patients with diffuse large B-cell lymphoma.
References
Beylot-Barry, M., Mermin, D., Maillard, A., Bouabdallah, R., Bonnet, N., Duval-Modeste, A. B., Mortier, L., Ingen-Housz-Oro, S., Ram-Wolff, C., Barete, S., Dalle, S., Maubec, E., Quereux, G., Templier, I., Bagot, M., Grange, F., Joly, P., Vergier, B., Vially, P. J., Gros, A., & Merlio, J. P. (2018). A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. The Journal of investigative dermatology, 138(9), 1982–1989. https://doi.org/10.1016/j.jid.2018.03.1516
Brasil. (2014). Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: Sistema GRADE – Manual de graduação da qualidade da evidência e força de recomendação para tomada de decisão em saúde: Ministério da Saúde. http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_sistema_grade.pdf
Bruna, R., Benedetti, F., Boccomini, C., Patti, C., Barbui, A. M., Pulsoni, A., Musso, M., Liberati, A. M., Gini, G., Castellino, C., Rossini, F., Ciceri, F., Rota-Scalabrini, D., Stelitano, C., Di Raimondo, F., Tucci, A., Devizzi, L., Zoli, V., Zallio, F., Narni, F., & Tarella, C. (2019). Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Haematologica, 104(11), 2241–2248. https://doi.org/10.3324/haematol.2018.209932
Chigurupati, S. V., Shukla, M., & Pandey, M. (2021). Primary sacral non-Hodgkin's lymphoma: report of a case and systematic review of literature. World journal of surgical oncology, 19(1), 61. https://doi.org/10.1186/s12957-021-02153-1
Davison, K., Chen, B. E., Kukreti, V., Couban, S., Benger, A., Berinstein, N. L., Kaizer, L., Desjardins, P., Mangel, J., Zhu, L., Djurfeldt, M. S., Hay, A. E., Shepherd, L. E., & Crump, M. (2017). Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial. Annals of oncology: official journal of the European Society for Medical Oncology, 28(3), 622–627. https://doi.org/10.1093/annonc/mdw653
Donato, H., & Donato, M. (2019). Etapas na Condução de uma Revisão Sistemática. Acta Médica Portuguesa, 32(3), 227-235.
Fajardo, L., Ramin, G. de A., Penachim, T. J., Martins, D. L., Cardia, P. P., & Prando, A. (2016). Manifestações abdominais do linfoma extranodal: ensaio iconográfico. Radiologia Brasileira, 49(6), 397–402. http://dx.doi.org/10.1590/0100-3984.2015.0201
Gleeson, M., Counsell, N., Cunningham, D., Chadwick, N., Lawrie, A., Hawkes, E. A., McMillan, A., Ardeshna, K. M., Jack, A., Smith, P., Mouncey, P., Pocock, C., Radford, J. A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J., & Linch, D. (2017). Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Annals of oncology: official journal of the European Society for Medical Oncology, 28(10), 2511–2516. https://doi.org/10.1093/annonc/mdx353
Guzauskas, G. F., Masaquel, A., Reyes, C., Bernaards, C., Krivasi, T., & Veenstra, D. L. (2018). Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. Journal of medical economics, 21(10), 960–967. https://doi.org/10.1080/13696998.2018.1489254
Hu, X., Zeng, M., Yang, S. E., Liang, X., Ding, S. S., Guo, L., Li, S., & Wen, S. J. (2017). Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. Medicine, 96(45), e8494. https://doi.org/10.1097/MD.0000000000008494
Illerhaus, G., Schorb, E., & Kasenda, B. (2018). Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood, 132(7), 681–688. https://doi.org/10.1182/blood-2018-01-791558
Iqbal, M., Reljic, T., Ayala, E., Sher, T., Murthy, H., Roy, V., Foran, J., Tun, H., Kumar, A., & Kharfan-Dabaja, M. A. (2020). Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(1), 76–82. https://doi.org/10.1016/j.bbmt.2019.08.019
Kuruvilla, J., MacDonald, D. A., Kouroukis, C. T., Cheung, M., Olney, H. J., Turner, A. R., Anglin, P., Seftel, M., Ismail, W. S., Luminari, S., Couban, S., Baetz, T., Meyer, R. M., Hay, A. E., Shepherd, L., Djurfeldt, M. S., Alamoudi, S., Chen, B. E., & Crump, M. (2015). Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood, 126(6), 733–738. https://doi.org/10.1182/blood-2015-01-622084
Leonard, J. P., Jung, S. H., Johnson, J., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Czuczman, M., Giguere, J. K., & Cheson, B. D. (2015). Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33(31), 3635–3640. https://doi.org/10.1200/JCO.2014.59.9258
Lopez-Santillan, M., Lopez-Lopez, E., Alvarez-Gonzalez, P., Martinez, G., Arzuaga-Mendez, J., Ruiz-Diaz, I., Guerra-Merino, I., Gutierrez-Camino, A., & Martin-Guerrero, I. (2021). Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review. Critical reviews in oncology/hematology, 165, 103430. https://doi.org/10.1016/j.critrevonc.2021.103430
Oliveira, L. S., Cruz, J. A. L., Rockenbach, M., & Dobrachinski, L. (2021). Aspectos clínicos e histopatológicos dos linfomas Hodking e não Hodking: uma revisão sistemática / Clinical and histopathological aspects of Hodking and non-Hodking lymphomas: a systematic review. Brazilian Journal of Development, 7(2), 15808–15815. https://doi.org/10.34117/bjdv7n2-280
Parrott, M., Rule, S., Kelleher, M., & Wilson, J. (2018). A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma. Clinical lymphoma, myeloma & leukemia, 18(1), 13–25.e6. https://doi.org/10.1016/j.clml.2017.10.004
Peng, Y. Y., Xiong, Y. Y., Zhang, L. X., Wang, J., Zhang, H. B., Xiao, Q., & Guo, S. L. (2021). Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma. Turkish journal of haematology : official journal of Turkish Society of Haematology, 38(2), 126–137. https://doi.org/10.4274/tjh.galenos.2021.2020.0438
Prisma Group. (2015). Preferred Reporting Items for Systematic Reviews and Meta-Analyses. University of Ottawa/Oxford University. http://www.prisma-statement.org/PRISMAStatement/.
Schorb, E., Finke, J., Ferreri, A. J., Ihorst, G., Mikesch, K., Kasenda, B., Fritsch, K., Fricker, H., Burger, E., Grishina, O., Valk, E., Zucca, E., & Illerhaus, G. (2016). High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC cancer, 16, 282. https://doi.org/10.1186/s12885-016-2311-4
Srour, S. A., Li, S., Popat, U. R., Qazilbash, M. H., Lozano-Cerrada, S., Maadani, F., Alousi, A., Kebriaei, P., Anderlini, P., Nieto, Y., Jones, R., Shpall, E., Champlin, R. E., & Hosing, C. (2017). A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. British journal of haematology, 178(4), 561–570. https://doi.org/10.1111/bjh.14731
Stephens, D. M., Li, H., LeBlanc, M. L., Puvvada, S. D., Persky, D., Friedberg, J. W., & Smith, S. M. (2016). Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 34(25), 2997–3004. https://doi.org/10.1200/JCO.2015.65.4582
Taverna, C., Martinelli, G., Hitz, F., Mingrone, W., Pabst, T., Cevreska, L., Del Giglio, A., Vanazzi, A., Laszlo, D., Raats, J., Rauch, D., Vorobiof, D. A., Lohri, A., Biaggi Rudolf, C., Rondeau, S., Rusterholz, C., Heijnen, I. A., Zucca, E., & Ghielmini, M. (2016). Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 34(5), 495–500. https://doi.org/10.1200/JCO.2015.61.3968
Yang, Y. T., Tai, C. J., Chen, C., Wu, H. C., Mikhaylichenko, N., Chiu, H. T., Chen, Y. Y., & Hsu, Y. E. (2016). Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. PloS one, 11(10), e0161811. https://doi.org/10.1371/journal.pone.0161811
Ying, Z., Yang, H., Guo, Y., Li, W., Zou, D., Zhou, D., Wang, Z., Zhang, M., Wu, J., Liu, H., Zhang, P., Yang, S., Zhou, Z., Zheng, H., Song, Y., & Zhu, J. (2021). Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer medicine, 10(3), 999–1011. https://doi.org/10.1002/cam4.3686
Zinzani, P. L., Flinn, I. W., Yuen, S., Topp, M. S., Rusconi, C., Fleury, I., Le Dû, K., Arthur, C., Pro, B., Gritti, G., Crump, M., Petrich, A., Samineni, D., Sinha, A., Punnoose, E. A., Szafer-Glusman, E., Spielewoy, N., Mobasher, M., Humphrey, K., Kornacker, M., & Hiddemann, W. (2020). Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood, 136(23), 2628–2637. https://doi.org/10.1182/blood.2020005588
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Bruno Antônio Rolim Coelho; Alanna Michely Batista de Morais
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
